Blog

DIALYSIS: Above All, Do No Harm

Every few years, a new industry becomes the apparent victim of Medicare’s regulatory wrath. First, the power scooter market, then ...

Healthcare: Nine Ways a Federal Slowdown Hits the Little Guy

THIS WAS AN OLD BLOG POST FROM THE LAST SET OF FEDERAL SHUTDOWNS. SOMEHOW SEEMS RELEVANT IN 2018-19, SO I'M ...

Medical Apps: FDA Forgets the ‘RH’ Factor, takes a ‘D’

Medical Apps: FDA Forgets the RH Factor, takes a D. This week, FDA finally gave us much ado about nothing ...

The Conversation” on New Drug Pricing: Are We There Yet? Part I: Policy perspectives on Sovaldi and other Hepatitis C drugs

We all know that someday, the US will need to tackle a long-avoided national “conversation” on healthcare… the one   ...